Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis
Objectives Both telitacicept and belimumab are approved for treating active systemic lupus erythematosus (SLE) in China. However, the economic value of these two drugs is unclear. Therefore, this study aims to evaluate the cost-effectiveness of telitacicept versus belimumab in SLE from the perspecti...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2026-01-01
|
| Col·lecció: | Lupus Science and Medicine |
| Accés en línia: | https://lupus.bmj.com/content/13/1/e001684.full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|